The HLA-B27 test (via flow cytometry) detects the HLA-B27 protein, aiding in the diagnosis of autoimmune disorders like ankylosing spondylitis.
The HLA-B27 Flow Cytometry test is a specialized blood test used to detect the presence of the HLA-B27 protein on white blood cells. HLA-B27 is a genetic marker associated with an increased risk of autoimmune conditions, particularly ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and certain types of uveitis. Identifying the HLA-B27 marker helps doctors diagnose and manage these autoimmune conditions, as well as assess the likelihood of their development.
The HLA-B27 test is a blood test that uses flow cytometry, a technique that enables precise analysis of the specific proteins on cells. In this case, it identifies the HLA-B27 protein, a variant of human leukocyte antigen (HLA) that can indicate susceptibility to certain autoimmune diseases. Flow cytometry is preferred for HLA-B27 detection because it offers higher accuracy, sensitivity, and speed compared to traditional methods.
The HLA-B27 test is recommended for individuals experiencing symptoms consistent with autoimmune disorders linked to the HLA-B27 antigen, such as Chronic back pain, particularly in young adults, which may suggest ankylosing spondylitis. Joint pain or swelling, possibly indicating reactive or psoriatic arthritis. Eye inflammation or recurrent episodes of uveitis. The test is particularly beneficial for those with a family history of autoimmune disorders or individuals who have unexplained symptoms that align with these conditions.
Diagnopein offers advanced HLA-B27 testing using state-of-the-art flow cytometry technology for the most accurate and reliable results. Diagnopein's experienced pathology lab centre ensure that every sample is handled with precision and care in a clean and well-maintained environment. Their commitment to timely and detailed reporting allows for quick follow-up with healthcare providers, which is essential for managing autoimmune conditions effectively. Diagnopein’s patient-centered approach provides clear guidance on pre-test instructions and professional consultation as needed.
A positive result means the HLA-B27 protein is present, which increases the risk of certain autoimmune diseases. However, not everyone with HLA-B27 will develop these conditions, and additional diagnostic tests are typically needed.
A negative result suggests the absence of the HLA-B27 marker, lowering the likelihood of associated autoimmune diseases, but it does not entirely rule them out.
Results are generally available within a few days, depending on laboratory processing times.
The test is safe and involves only a standard blood draw, with minor risks of discomfort or bruising at the puncture site.
